Persistent Post-COVID Conditions Remain Despite Paxlovid Treatment
A retrospective study of over 9,500 veterans found that nirmatrelvir-ritonavir, a treatment for COVID-19, does not reduce the incidence of most post-COVID conditions (PCCs), except for thromboembolic events. The study analyzed 31 different conditions and found no statistically significant reduction in other PCCs. The results contradict a smaller study that reported lower incidence of 10 out of 13 PCCs. The authors suggest that PCCs may not be a significant factor in COVID-19 treatment decisions based on these findings.